Table 2. Details of patients who had discontinued entecavir.
| Reason | Number of patients |
|---|---|
| Unwilling to commit to long-term treatment or had financial difficulty | 49 |
| Genotypic resistance to entecavir | 2 |
| Virologic breakthrougha | 1 |
| Switch to alternative anti-virals because of pregnancy | 3 |
| HBsAg seroconversionb | 1 |
| Deathc | 5 |
| Total | 61 |
Abbreviations: HBsAg, hepatitis B surface antigen; HBV DNA, hepatitis B virus DNA.
a
Virologic breakthrough without genotypic resistance.
b
Patient who had HBsAg seroconversion and undetectable HBV DNA can opt to stop anti-viral after discussion with physician.
c
Two patients died of hepatocellular carcinoma, 1 died of decompensated cirrhosis, and 2 died of diseases unrelated to chronic hepatitis B infection (carcinoma of lung and subarachnoid hemorrhage, respectively).